SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
June 9, 2020 (June 1, 2020)
CALMARE THERAPEUTICS INCORPORATED
(Exact name of registrant as specified in its charter)
| Delaware |
|
001-08696 |
|
36-2664428 |
| (State or other jurisdiction |
|
(Commission File Number) |
|
(IRS Employer |
| of Incorporation) |
|
|
|
Identification Number) |
1375 Kings Highway East
Fairfield, CT 06824
(Address of principal executive offices)
203-368-6044
(Registrant’s Telephone Number)
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: None
| Title of each class | |
Trading Symbol(s) | |
Name of each exchange on which registered |
| | |
| |
|
Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 1.01 | Entry into a Material Definitive Agreement. |
On June 1, 2020, Calmare Therapeutics Incorporated
(the “Registrant”) was awarded Federal Supply Schedule Contract 36F79720D0118 (the “Agreement”),
effective June 15, 2020, by the U.S. Department of Veterans Affairs (the “VA”). The Agreement authorizes $2,500,000
of orders by the VA for Calmare® Pain Therapy Devices. The Agreement was awarded under Schedule 65 II A-Medical.
Equipment and Supplies under Federal Supply Schedule Solicitation RFP-797-FSS-99-0025-R9 and has a term of 5 years. A redacted
copy of the award letter is provided in this Form 8-K as Exhibit 10.1.
On June 9, 2020, the Registrant issued a press
release titled “Calmare Therapeutics Awarded $2.5 Million, Five-Year Contract by U.S. Department of Veteran Affairs for Calmare®
Pain Therapy Devices”. A copy of the press release is provided in this Form 8-K as Exhibit 99.1.
The information in Item 8.01 of this Form 8-K is
being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934,
or otherwise subject to the liabilities of that section. The information in Item 8.01 of this Form 8-K also shall not be deemed
to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of
1934, except to the extent that the Company specifically incorporates it by reference.
| ITEM 9.01. | Financial Statements and Exhibits |
Exhibits.
| 10.1 |
Letter, dated June 1, 2020, from U.S. Federal Supply Schedule Service to Calmare Therapeutics Incorporated awarding Federal Supply Schedule Contract 36F79720D0118, effective June 15, 2020, by the U.S. Department of Veterans Affairs to Calmare Therapeutics Incorporated. |
| 99.1 |
Press Release, dated June 9, 2020, titled “Calmare Therapeutics Awarded $2.5 Million, Five-Year Contract by U.S. Department of Veteran Affairs for Calmare® Pain Therapy Devices”. |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
| June
9, 2020 |
By: |
/s/
Conrad Mir |
| |
|
Conrad
Mir |
| |
|
Chief
Executive Officer |
2
